Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of safety and efficacy of voriconazole in real-life setting in the treatment of high risk patients with invasive fungal infections. The study is conducted in Slovakia only.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Voriconazole

Criteria

Inclusion Criteria:

• Male or female patient of age 2 years or older.

• High-risk patients with proven, probable or possible invasive fungal infection (IFI) according to the EORTC/MSG criteria.

• Patients indicated for secondary prophylaxis of invasive aspergillosis.

Exclusion Criteria:

• Patients with known hypersensitivity to voriconazole or to any of the excipients.

• Patients with contraindicated concomitant medications according to the SmPC.

• Children less than 2 years of age.

• Pregnancy and lactation.